Orphan Medical Xyrem
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA extends its NDA review goal for the narcolepsy therapy sodium oxybate oral solution by 90 days, to early July, to review recently submitted data requested by the agency. FDA's Peripheral and Central Nervous System Advisory Committee is expected to schedule a June review of the dru
You may also be interested in...
Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance
The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.
Intuitive Exceeds Expectations In Q1 As Da Vinci Sales And Surgeries Recover
The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.
California DTSC Eyes Hair Relaxers, Straighteners For Next Safer Consumer Product Priority
The Department of Toxic Substances Control does not identify specific chemicals of concern in its 2021-2023 Priority Product Draft Work Plan, but says it is focusing on ingredients and endpoints associated with children, women of childbearing age, communities of color and aquatic impacts.